The global clinical trial software market is projected to grow at a CAGR of 14.3% from 2024 to 2031, reaching a valuation of US$ 2.3 billion. This growth is driven by the increasing adoption of digital health solutions, especially in the wake of the COVID-19 pandemic, and a growing demand for patient-centric clinical trial solutions.